Patients with cancer treated at Mayo Clinic in Jacksonville, Florida safely received intravenous chemotherapy in their homes through a pilot program designed to reduce the burden of treatment while ...

A novel combination of an investigational intravesical drug delivery system designed to provide sustained release of gemcitabine into the bladder (Gem-iDRS, Inlexzo) and systemic treatment with the ...

In a study published in NEJM Catalyst, Mayo Clinic researchers demonstrate that chemotherapy can be safely delivered in patients' homes. The study evaluated Mayo Clinic's Cancer CARE Beyond Walls ...

Bladder cancer can cause pain when it spreads to different areas of the body. From NSAIDs to nerve blocks, here are the ...

As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...

A real-world US community-based evaluation of recurrence among non-muscle-invasive bladder cancer patients treated with bacillus Calmette-Guérin. Description and management strategies of prespecified ...

Liquid biopsy-based detection of MTAP gene loss in non-muscle invasive bladder cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary Cancers Symposium. This abstract does not ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with muscle-invasive bladder cancer, even those eligible for cisplatin ...

Event-free survival improved with EV/pembro: median not reached vs 48.5 months, and 24‑month EFS 79.4% vs 66.2% with cisplatin/gemcitabine. Overall survival separated early (24‑month 86.9% vs 81.3%), ...

Abstract: Implantable chemoports are routinely utilized in oncology for the administration of intermittent chemotherapy infusion with constrained venipuncture. Routine chemoports are marred by ...